Literature DB >> 18519886

HIV prevention for injecting drug users: the first 25 years and counting.

Don C Des Jarlais1, Salaam Semaan.   

Abstract

During the last three decades, both the injection of illicit psychoactive drugs and HIV infection among injecting drug users (IDUs) have spread throughout industrialized and developing countries. Extremely rapid transmission of HIV has occurred in IDU populations with incidence rates of 10 to 50/100 person-years. In sharp contrast, there are many examples of very effective HIV risk reduction for IDUs, both in preventing initial epidemics and in bringing existing epidemics under control. IDUs are capable of learning basic information about HIV/AIDS and modifying their behavior to protect both themselves and their peers. Effective HIV prevention for IDUs requires programs that treat IDUs with dignity and respect, provide accurate information and the means for behavior change-access to sterile injection equipment, condoms, and drug abuse treatment. Programs that provide these services need to be implemented on a public health scale for IDU populations at risk for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519886     DOI: 10.1097/PSY.0b013e3181772157

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  47 in total

1.  Clinical implications of drug abuse epidemiology.

Authors:  Jeffrey D Schulden; Marsha F Lopez; Wilson M Compton
Journal:  Psychiatr Clin North Am       Date:  2012-06

2.  Substance abuse treatment as HIV prevention: more questions than answers.

Authors:  Lawrence S Brown; Steven Kritz; Edmund J Bini; Ben Louie; Jim Robinson; Donald Alderson; John Rotrosen
Journal:  J Natl Med Assoc       Date:  2010-12       Impact factor: 1.798

3.  The influence of the perceived consequences of refusing to share injection equipment among injection drug users: balancing competing risks.

Authors:  Karla D Wagner; Stephen E Lankenau; Lawrence A Palinkas; Jean L Richardson; Chih-Ping Chou; Jennifer B Unger
Journal:  Addict Behav       Date:  2011-03-25       Impact factor: 3.913

4.  Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Patrick; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2013-08-30       Impact factor: 4.492

Review 5.  Toward a comprehensive approach to HIV prevention for people who use drugs.

Authors:  Brandon D L Marshall; Evan Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

6.  HIV seroprevalence in a sample of Tanzanian intravenous drug users.

Authors:  Mark L Williams; Sheryl A McCurdy; Anne M Bowen; Gad P Kilonzo; John S Atkinson; Michael W Ross; M T Leshabari
Journal:  AIDS Educ Prev       Date:  2009-10

7.  Is injection serosorting occurring among HIV-positive injection drug users? Comparison by injection partner's HIV status.

Authors:  Yuko Mizuno; David W Purcell; Lisa R Metsch; Cynthia A Gomez; Amy R Knowlton; Mary H Latka
Journal:  J Urban Health       Date:  2011-12       Impact factor: 3.671

8.  Associations of place characteristics with HIV and HCV risk behaviors among racial/ethnic groups of people who inject drugs in the United States.

Authors:  Sabriya L Linton; Hannah L F Cooper; Mary E Kelley; Conny C Karnes; Zev Ross; Mary E Wolfe; Yen-Tyng Chen; Samuel R Friedman; Don Des Jarlais; Salaam Semaan; Barbara Tempalski; Catlainn Sionean; Elizabeth DiNenno; Cyprian Wejnert; Gabriela Paz-Bailey
Journal:  Ann Epidemiol       Date:  2016-08-08       Impact factor: 3.797

Review 9.  Substance abuse in the United States: findings from recent epidemiologic studies.

Authors:  Jeffrey D Schulden; Yonette F Thomas; Wilson M Compton
Journal:  Curr Psychiatry Rep       Date:  2009-10       Impact factor: 5.285

10.  Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now?

Authors:  Richard S Garfein; Thomas J Stopka; Patricia B Pavlinac; Alessandra Ross; B Karen Haye; Elise D Riley; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.